Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Herbst, RS; Baas, P; Perez-Gracia, JL; Felip, E; Kim, DW; Han, JY; Molina, JR; Kim, JH; Arvis, CD; Ahn, MJ; Majem, M; Fidler, MJ; Surmont, V; de Castro, G; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, EH; Lubiniecki, GM; Garon, EB

Herbst, RS (reprint author), Yale Sch Med, Yale Comprehens Canc Ctr, 333 Cedar St,WWW221, New Haven, CT 06520 USA.

ANNALS OF ONCOLOGY, 2019; 30 (2): 281

Abstract

Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索